Journal
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Volume 22, Issue 5, Pages 517-523Publisher
WILEY
DOI: 10.1002/pds.3423
Keywords
pharmacovigilance; drug safety surveillance; adverse events; data mining; scan statistics; clusters; pharmacoepidemiology
Funding
- Agency for Healthcare Research and Quality (AHRQ) [U18 HS 010391]
- AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010391] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Purpose In post-marketing drug safety surveillance, data mining can potentially detect rare but serious adverse events. Assessing an entire collection of drugevent pairs is traditionally performed on a predefined level of granularity. It is unknown a priori whether a drug causes a very specific or a set of related adverse events, such as mitral valve disorders, all valve disorders, or different types of heart disease. This methodological paper evaluates the tree-based scan statistic data mining method to enhance drug safety surveillance. Methods We use a three-million-member electronic health records database from the HMO Research Network. Using the tree-based scan statistic, we assess the safety of selected antifungal and diabetes drugs, simultaneously evaluating overlapping diagnosis groups at different granularity levels, adjusting for multiple testing. Expected and observed adverse event counts were adjusted for age, sex, and health plan, producing a log likelihood ratio test statistic. Results Out of 732 evaluated disease groupings, 24 were statistically significant, divided among 10 non-overlapping disease categories. Five of the 10 signals are known adverse effects, four are likely due to confounding by indication, while one may warrant further investigation. Conclusion The tree-based scan statistic can be successfully applied as a data mining tool in drug safety surveillance using observational data. The total number of statistical signals was modest and does not imply a causal relationship. Rather, data mining results should be used to generate candidate drugevent pairs for rigorous epidemiological studies to evaluate the individual and comparative safety profiles of drugs. Copyright (c) 2013 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available